AICAR (Acadesine): Complete Research Profile — AMPK Activator & Exercise Mimetic (2026)

# AICAR (Acadesine): Complete Research Profile — AMPK Activator & Exercise Mimetic (2026)

AICAR — 5-Aminoimidazole-4-carboxamide ribonucleoside (also called acadesine or AICA ribonucleoside) — occupies a unique position in metabolic research. As a potent activator of AMP-activated protein kinase (AMPK), AICAR has been used for decades in research to study AMPK-mediated pathways in metabolism, cardiovascular function, and cellular energy homeostasis. Its most controversial research finding — that it significantly enhanced endurance performance in sedentary mice without any exercise training — earned it the label "exercise in a pill" and a permanent spot on the World Anti-Doping Agency (WADA) prohibited list.

This profile covers AICAR's mechanism of action, downstream metabolic effects, research evidence across multiple domains, its WADA ban and detection history, safety considerations, and frequently asked questions.

> Research Disclaimer: This article is for educational and informational purposes only. AICAR is a research compound banned in competitive sport by WADA. This content does not constitute medical advice or endorsement of any use outside of controlled research settings.

---

What Is AICAR?

AICAR is a naturally occurring intermediate in purine biosynthesis pathways — small amounts are produced endogenously in all human cells. In research settings, exogenously administered AICAR is taken up into cells via nucleoside transporters (primarily ENT1, the equilibrative nucleoside transporter 1) and phosphorylated intracellularly to form ZMP (AICA ribonucleotide monophosphate).

Key identifiers:

• •Full name: 5-Aminoimidazole-4-carboxamide ribonucleoside
• •Synonyms: Acadesine, AICA ribonucleoside, NSC 105823
• •Molecular weight: 338.32 g/mol
• •CAS number: 2627-69-2
• •Structure: Adenosine analog with modified base
• •Research platform: 27 listings on Peptides.SO

Historical Background: AICAR was initially researched as a cardioprotective agent, with early studies showing it could reduce ischemia-reperfusion injury in cardiac tissue. Its AMPK-activating properties were characterized extensively through the 1990s and 2000s, making it the most commonly used pharmacological tool for studying AMPK biology.

---

Mechanism of Action

AMPK Activation Pathway

ZMP — the intracellular metabolite of AICAR — is a structural mimic of AMP (adenosine monophosphate). ZMP binds to the AMP-sensing regulatory subunit (gamma subunit) of AMPK, the same site where physiological AMP binds during energy-depleted states.

AMPK is the master cellular energy sensor. When cellular energy is low (high AMP:ATP ratio — during exercise, fasting, or caloric restriction), AMPK is activated to:

• •Switch off anabolic, energy-consuming processes
• •Switch on catabolic, energy-generating processes
• •Restore cellular energy balance

By mimicking AMP, ZMP from AICAR tricks AMPK into sensing a low-energy state even when energy levels are normal — thereby activating the full downstream program of AMPK without actual metabolic stress.

Biochemical Cascade:

1. AICAR enters cells via ENT1 nucleoside transporter

2. Intracellular phosphorylation converts AICAR → ZMP

3. ZMP binds AMPK gamma subunit (AMP-binding site)

4. AMPK undergoes allosteric activation and becomes phosphorylated at Thr172 by upstream kinases (LKB1, CaMKK2)

5. Activated AMPK triggers downstream substrate phosphorylation cascade

Key Downstream Effects of AMPK Activation

Metabolic Switching:

• •Fat oxidation (beta-oxidation): AMPK activates carnitine palmitoyltransferase 1 (CPT1), the rate-limiting step in fatty acid transport into mitochondria for oxidation
• •Glucose uptake: AMPK promotes GLUT4 translocation to the plasma membrane, increasing glucose uptake independent of insulin
• •Glycogen synthesis inhibition: AMPK phosphorylates and inactivates glycogen synthase, redirecting glucose toward energy production

Mitochondrial Biogenesis:

• •AMPK activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha), the master regulator of mitochondrial biogenesis
• •Increased PGC-1α drives expression of oxidative phosphorylation genes and new mitochondria formation
• •Results in greater mitochondrial density and oxidative capacity in skeletal muscle

Anabolic Suppression:

• •AMPK phosphorylates and inhibits mTORC1 (mechanistic target of rapamycin complex 1), reducing protein synthesis and cell growth
• •Inhibits fatty acid and cholesterol synthesis via inactivation of ACC (acetyl-CoA carboxylase) and HMG-CoA reductase

Autophagy Activation:

• •AMPK promotes autophagy (cellular recycling) via ULK1 phosphorylation
• •Autophagy clears dysfunctional organelles, including damaged mitochondria (mitophagy)

AMPK-Independent Effects: An Important Caveat

A critical body of research (systematically reviewed in Cell Biology, 2021) has established that numerous effects previously attributed to AICAR's AMPK activation are actually AMPK-independent. ZMP can inhibit other enzymes in purine biosynthesis (ADENYLOSUCCINATE LYASE, ATIC) and affect multiple cellular targets beyond AMPK. This means AICAR research findings cannot be entirely attributed to AMPK, and mechanistic interpretation of AICAR studies requires careful consideration of potential off-target effects.

---

Exercise Mimetic Research

The most widely cited finding in AICAR research comes from a landmark 2008 study in Cell by Narkar et al. demonstrating that AICAR functions as an exercise mimetic — triggering metabolic adaptations associated with endurance training without physical exercise.

The 2008 Cell Study: "Exercise in a Pill"

Key finding: Four weeks of AICAR treatment in sedentary mice — with no exercise training — induced a program of oxidative metabolic gene expression in skeletal muscle and enhanced treadmill running endurance by 44% without any physical activity.

AICAR treatment produced:

• •Upregulation of genes associated with oxidative metabolism (slow-twitch muscle fiber phenotype)
• •Increased fatty acid oxidation capacity in skeletal muscle
• •Improved mitochondrial function markers
• •Enhanced endurance performance on standardized treadmill testing

This study established AICAR as the prototypical exercise mimetic and attracted intense interest from both the sports performance and metabolic disease research communities.

Skeletal Muscle Adaptation Research

Subsequent studies elaborated the AICAR-induced skeletal muscle phenotype:

Fiber Type Shifting: AICAR treatment promotes a shift from glycolytic (fast-twitch, Type IIb) to oxidative (slow-twitch, Type I/IIa) muscle fiber characteristics. This shift mirrors the adaptations seen in endurance-trained athletes.

Mitochondrial Density: AICAR increases mitochondrial biogenesis in skeletal muscle via PGC-1α activation, improving the muscle's capacity for sustained aerobic energy production.

Fat vs. Glucose Fuel Preference: AICAR-treated muscle preferentially oxidizes fatty acids, sparing glycogen and improving metabolic efficiency — effects central to endurance performance.

---

Metabolic Disease Research

Beyond exercise physiology, AICAR has been studied across multiple metabolic disease models:

Insulin Resistance and Type 2 Diabetes

AICAR's AMPK-activating properties have been studied in insulin resistance models:

• •Promotes GLUT4-mediated glucose uptake independently of insulin, offering a potential bypass of insulin resistance
• •Reduces hepatic glucose production (HGP) by suppressing gluconeogenic enzymes
• •Improves insulin sensitivity markers in animal models of diet-induced obesity

Diabetic Neuropathy

A 2025 study in the International Journal of Molecular Sciences demonstrated that AICAR administration prevented and reversed diabetic polyneuropathy (DPN) in experimental models by regulating mitophagy — the selective autophagy of dysfunctional mitochondria. AMPK activation promoted mitochondrial quality control in peripheral neurons, reducing the metabolic damage underlying diabetic neuropathic pain.

Cardiovascular Protection

AICAR's original research rationale — cardiac protection — remains an active area:

• •AICAR reduces ischemia-reperfusion injury in cardiac tissue by activating cardioprotective AMPK pathways
• •Reduces inflammatory signaling in vascular endothelial cells
• •Improves vascular function markers in experimental models of cardiovascular disease

Fatty Liver and Metabolic Liver Disease

AMPK activation reduces hepatic lipid accumulation by:

• •Inhibiting de novo lipogenesis (via ACC inhibition)
• •Promoting hepatic fatty acid oxidation (via CPT1 activation)
• •Reducing VLDL secretion

AICAR has demonstrated reductions in hepatic steatosis in animal models of non-alcoholic fatty liver disease (NAFLD).

Cancer Research

AICAR is studied in oncology research for its AMPK-mediated antiproliferative effects:

• •mTORC1 inhibition by AMPK reduces cancer cell growth and angiogenesis
• •AMPK activation can trigger cell cycle arrest in some cancer cell lines
• •AICAR's effect on purine biosynthesis independently interferes with nucleotide synthesis in rapidly dividing cells

---

WADA Prohibition and Doping History

Why WADA Banned AICAR

Following the 2008 exercise mimetic research, WADA added AICAR to the Prohibited List in 2009 under the category of metabolic modulators. The rationale: AICAR's ability to enhance endurance performance without exercise training represents an unfair performance advantage inconsistent with the spirit of sport.

AICAR is classified alongside GW501516 (GW1516), another metabolic modulator banned in the same period. Both compounds demonstrated exercise-mimetic properties in animal models.

Detection Methods

WADA has funded multiple research programs to develop reliable detection methods:

Urinary Threshold Method:

Because AICAR is endogenously produced in small amounts, WADA established a threshold-based approach. Urinary AICAR concentrations above 3,500 ng/mg creatinine are considered inconsistent with normal endogenous production in healthy humans and indicative of exogenous administration.

Red Blood Cell (Erythrocyte) Method:

After cellular uptake, AICAR is converted to AICAR ribotide within red blood cells. AICAR ribotide concentrations in erythrocytes remain elevated for up to 10 days following exogenous AICAR administration — providing a detection window significantly longer than urinary methods.

Carbon Isotope Ratio (CIR) Testing:

By analogy with steroid detection, carbon isotope ratio mass spectrometry can distinguish synthetic (isotopically lighter) exogenous AICAR from endogenous AICAR. WADA has funded research into CIR methods for AICAR as a confirmatory approach.

Current Status: Multiple detection methods are now validated and implemented in WADA-accredited testing laboratories. AICAR is routinely screened in anti-doping samples from competitive athletes.

---

Comparison to Other AMPK Activators

AICAR remains widely used in AMPK research despite its AMPK-independent effects, because it is commercially available, well-characterized, and produces robust AMPK activation in cell and animal models. More selective AMPK activators (A-769662, Compound 991) are increasingly used in mechanistic research to isolate AMPK-specific effects.

---

Research Safety Considerations

Preclinical Safety Profile

In animal models, AICAR administration produces dose-dependent effects with a defined safety window. High-dose AICAR can cause:

• •Hypoglycemia (via increased glucose uptake and reduced hepatic glucose production)
• •Cardiac effects (AMPK activation in heart muscle alters energy metabolism and contractility)
• •Effects on purine metabolism (via ATIC inhibition at high doses)

Clinical Research History

AICAR was investigated as a cardioprotective agent in clinical settings (originally as acadesine) in the 1990s and early 2000s. Clinical trials for ischemic preconditioning in cardiac surgery were conducted, though regulatory approval was not obtained. These trials provided important safety characterization in human subjects.

Key Research Considerations for Laboratory Use

• •Hypoglycemia risk: AICAR activates GLUT4-mediated glucose uptake independently of insulin; glycemic monitoring is important in animal experiments
• •Off-target effects: ZMP inhibits purine biosynthesis enzymes, potentially affecting nucleotide metabolism at high doses
• •AMPK-independent pathways: Research conclusions should account for potential AMPK-independent mechanisms when using AICAR as an AMPK research tool
• •Species differences: AICAR pharmacokinetics and tissue distribution vary across species; translating animal findings to human research contexts requires careful consideration

---

Research Procurement

Peptides.SO lists 27 vendors offering research-grade AICAR for laboratory research. Key quality parameters for research procurement:

• •Purity: ≥98% HPLC purity recommended for biochemical assays
• •Certificate of Analysis: Verify mass spectrometry confirmation of molecular identity
• •Solubility: AICAR has good aqueous solubility; confirm solubility specifications for intended research application
• •Storage: Stable at −20°C when stored dry; avoid repeated freeze-thaw cycles

Use our peptide comparison tool to evaluate vendor options and our peptide calculator for research concentration frameworks.

---

Frequently Asked Questions

Q: What is AICAR used for in research?

AICAR (acadesine) is primarily used as a pharmacological tool to activate AMPK in cell and animal research. It is studied in metabolic disease (insulin resistance, type 2 diabetes, fatty liver), exercise physiology (as an exercise mimetic), cardiovascular protection, cancer biology, and neuroprotection research.

Q: What does AICAR do to the body in research models?

AICAR activates AMPK, triggering a shift toward fat oxidation, increased glucose uptake, mitochondrial biogenesis, and autophagy activation. In animal models, it enhances endurance performance, reduces liver fat, improves insulin sensitivity, and protects against ischemia-reperfusion injury.

Q: Why is AICAR banned in sport?

WADA banned AICAR in 2009 after research demonstrated it enhanced endurance performance by 44% in sedentary mice without any training — an exercise mimetic effect that constitutes an unfair performance advantage. It is on WADA's Prohibited List as a metabolic modulator.

Q: Can AICAR be detected in drug tests?

Yes. WADA has developed multiple detection methods: urinary threshold testing (>3,500 ng/mg creatinine), red blood cell AICAR ribotide detection (detection window up to 10 days), and carbon isotope ratio testing. AICAR is routinely screened in competitive sport anti-doping samples.

Q: Is AICAR the same as acadesine?

Yes. AICAR and acadesine are the same compound — 5-Aminoimidazole-4-carboxamide ribonucleoside. Acadesine is the International Nonproprietary Name (INN) used in pharmaceutical contexts; AICAR is the abbreviation used in biochemistry research.

Q: How does AICAR compare to metformin as an AMPK activator?

Metformin activates AMPK indirectly, primarily through mitochondrial complex I inhibition and subsequent LKB1-mediated AMPK activation. AICAR activates AMPK more directly via ZMP/AMP mimicry. AICAR produces more pronounced and consistent AMPK activation in research settings, but metformin is clinically approved for diabetes. AICAR has greater AMPK-independent off-target effects than many more selective AMPK activators.

Q: Are there more selective AMPK activators than AICAR?

Yes. More selective AMPK activators include A-769662 (direct beta-subunit allosteric activator) and Compound 991. These compounds activate AMPK with greater selectivity and fewer off-target effects than AICAR. However, AICAR remains widely used due to its commercial availability and extensive existing literature.

Q: What is the connection between AICAR and exercise physiology?

AICAR's 2008 landmark study in Cell demonstrated that 4 weeks of AICAR treatment in sedentary mice enhanced treadmill endurance by 44% without exercise, triggering a skeletal muscle gene expression program mimicking endurance training. This established AICAR as the definitive exercise mimetic research tool and drove its addition to the WADA prohibited list.

Q: Does AICAR have AMPK-independent effects?

Yes, and this is an important research consideration. A 2021 systematic review in Cell Biology documented that numerous effects previously attributed to AMPK activation are actually AMPK-independent — primarily through ZMP's inhibition of purine biosynthesis enzymes (ADENYLOSUCCINATE LYASE, ATIC). Research using AICAR as an AMPK probe should use appropriate AMPK-knockout controls and ideally validate findings with more selective AMPK activators.

---

Key Research References

1. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cell Biology, 2021.

2. Administration of AICAR Prevents and Reverses Diabetic Polyneuropathy via Mitophagy. International Journal of Molecular Sciences, 2025.

3. Narkar VA, et al. AMPK and PPARδ Agonists Are Exercise Mimetics. Cell, 2008. [Landmark exercise mimetic study establishing AICAR's endurance effects]

4. WADA: Detection of AICAR administration by carbon isotope ratio mass spectrometry. WADA Scientific Research.

5. WADA: AICAR ribotide in red blood cells as long-term marker. WADA Scientific Research.

6. AICAr AMPK-Independent Effects Review. Cells (MDPI), 2021.

---

Further Reading:

• •Irisin (FNDC5): Complete Research Profile — The Exercise-Induced Myokine in Metabolic, Neuroprotection, and Bone Biology Research (2026)
• •Retatrutide (LY3437943): Triple Hormone Receptor Agonist — Complete Research Profile
• •HCG (Human Chorionic Gonadotropin): Complete Research Profile — LH-Mimetic Glycoprotein Hormone in Reproductive Biology, Hypogonadism, and Hormonal Research (2026)
• •MGF (Mechano Growth Factor / IGF-1Ec): Complete Research Profile — The Mechanosensitive IGF-1 Splice Variant in Muscle, Neural, and Cardiac Research (2026)
• •Dosage Chart

---

This article is for educational and research purposes only. AICAR is a WADA-prohibited substance banned in competitive sport. This content does not constitute medical advice or endorsement of any particular use.